Royalty Pharma plc purchased a 1 % royalty interest in Alnylam Pharmaceuticals’ RNAi therapeutic AMVUTTRA from Blackstone Life Sciences for $310 million. The royalty covers worldwide net sales of AMVUTTRA through March 2035, with payments beginning October 1 2025.
AMVUTTRA, FDA‑approved for transthyretin amyloidosis (ATTR), generated approximately $1 billion in sales in 2024, up 74 % year‑over‑year. Alnylam reported Q3 2025 revenues of $1.25 billion, with AMVUTTRA contributing $685 million, underscoring the drug’s commercial momentum.
The acquisition aligns with Royalty Pharma’s strategy of acquiring royalties on approved products to generate consistent cash flow. The $310 million investment expands the company’s portfolio into the ATTR market, which is projected to grow as diagnosis rates rise and new therapies enter the market.
Royalty Pharma’s Q3 2025 earnings, released on November 5 2025, showed revenue of $1.2 billion and net income of $350 million, indicating a strong financial position to support the new royalty investment.
AMVUTTRA faces potential competition from Alnylam’s follow‑on product nucresiran, which is in late‑stage development. However, AMVUTTRA’s established market presence and the company’s robust sales trajectory mitigate short‑term competitive risks.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.